The North American Marijuana Index, a stock index that tracks the top performing cannabis stocks in the U.S. and Canada, decreased 3% in June as continued losses in Canada closed out the Index’s second worst performing quarter since its inception in January 2015.
Tag Archives: GWPH
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex (cannabidiol) Data Released by the American Academy of Neurology
LONDON, April 18, 2017 /Weed Wire/ – GW Pharmaceuticals noted that the American Academy of Neurology (AAN) issued a press release today announcing positive results from a second Phase 3 study (GWPCARE3) of Epidiolex.
GW Pharmaceuticals Announces Epidiolex® Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Lennox-Gastaut Syndrome
LONDON, March 29, 2017 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW’s investigational product Epidiolex®.
A Survey Of The North American Marijuana Index - Part One
In this survey we will be reviewing the stocks that make up the North American Marijuana Index. In Part 1, we’ll look at Canopy Growth Corp. (OTCPK:TWMJF), GW pharmaceuticals (NASDAQ:GWPH), Axim Biotechnologies Inc. (OTCQB:AXIM), and United Cannabis Corp. (OTCQB:CNAB).
Mentor Capital Acquires $1.0 Million of GW Pharmaceuticals, Plc
SAN DIEGO, Calif., March 3, 2017/Weed Wire/ — Mentor Capital, Inc. (OTCQB: MNTR) announced it has taken a $1.0 million position in the stock of GW Pharmaceuticals, Plc (NASDAQ: GWPH), a United Kingdom based group developing a portfolio of cannabinoid prescription medicines.
GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma
LONDON, Feb. 7, 2017 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study.
Institutional Cannabis: Defining Institutional Stakeholders
For the purpose of this column we consider three types of institutions: government, academic and corporate. They are the thought leaders, market leaders and mainstream actors from outside the industry that are stakeholders in the effects of an economic outcome.
GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome
LONDON, Dec. 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced additional positive Epidiolex® (cannabidiol or CBD) Phase 3 data in poster presentations at the 70th Annual Meeting of the American Epilepsy Society.
Investors Seek High Returns in Marijuana Stocks
For investors, the rising prospects of legalized pot may be too good to pass up, yet the publicly traded cannabis companies may not be such a smart bet.
GWPH Riding High: Stock Rising on Clinical Trial’s Positive Results
On Sept. 26, 2016, GW Pharmaceuticals (Nasdaq:GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for its third study in the United States on the efficacy of Epidiolex, its experimental CBD-based drug, in treating seizures associated with Lennox-Gastaut syndrome.
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
LONDON, Sept. 26, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) announces positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex.
Exclusive: GW Pharmaceuticals Hires Investment Bank Following Approaches - Sources
GW Pharmaceuticals Plc (Nasdaq:GWPH), a developer of marijuana-based epilepsy treatments, is working with an investment bank after other drugmakers approached it to express interest in an acquisition, people familiar with the matter said.
GW Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
LONDON, Sept. 7, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference.
GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress
LONDON, Aug. 9, 2016 /Weed Wire/ — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the third quarter ended 30 June 2016.
GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising $289.8 Million on the NASDAQ Global Market and Full Exercise of Underwriter’s Option to Purchase Additional ADSs
LONDON, July 18, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced offering on the NASDAQ Global Market.
Georgia’s Medical Marijuana Law Just Turned One Year Old
The phones at the Georgia Department of Public Health no longer ring off the hook with people calling to find doctors or asking questions about how the state’s medical marijuana registry works.
Here’s Why This Marijuana Drug Company’s Stock Is Soaring Today
GW Pharmaceuticals (NASDAQ:GWPH) could be on its way to eventually winning the first U.S. approval for a marijuana-based prescription drug.
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
LONDON, June 27, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”) announces positive results of the first randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.
GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS)
LONDON, June 21, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq: GWPH) (AIM: GWP) (“GW” or “the Company”) today announced that the Company has selected infantile spasms (IS) as the fourth target indication for its Epidiolex orphan pediatric epilepsy development program.
GW Pharmaceuticals to Present at the 2016 UBS Global Healthcare Conference on 24 May
LONDON, May 16, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016, at 8:00 a.m. (EDT) at the Grand Hyatt Hotel in New York City.
GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress
LONDON, May 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (AIM:GW) (the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the second quarter and half-year ended 31 March 2016.
GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference on 10 May
LONDON, May 4, 2016 /Weed Wire/ — GW Pharmaceuticals announced that Justin Gover, GW’s Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Healthcare Conference on Tuesday, May 10, 2016, at 9:20 a.m. (PDT) at the Encore at the Wynn Las Vegas, Las Vegas, Nev.
Epidiolex in Utah: Decrease in Seizure Frequency and Severity
In September 2014, The University of Utah’s Division of Pediatric Neurology and Primary Children’s Medical Center started the first of three clinical trials on the efficacy of Epidiolex, a nonpsychoactive cannabidiol-based drug from GW Pharmaceuticals (NASDAQ: GWPH).
7 Most Powerful People in America’s Marijuana Industry
America’s marijuana industry has bloomed in recent years with voters in more and more states voting to legalize pot in some form as public opinion on the drug seems to evolve with each generation.
GW Pharma Receives FDA Orphan Drug Designation for Cannabidiol
On April 21, 2016, GW Pharmaceuticals (NASDAQ: GWPH), a biopharma company with two promising cannabis-based medications, announced it had received Orphan Drug Designation for cannabidiol in the treatment of Tuberous Sclerosis Complex.
Doctors Are Getting on Board with Connecticut’s Push for Children’s Medical Marijuana
In a reversal of policy, the Connecticut arm of the American Academy of Pediatrics (AAP) has reportedly gotten on board with an effort to expand medical marijuana legalization to sick children in the state.
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
LONDON, April 11, 2016 /Weed Wire/ — GW Pharmaceuticals plc today announced that it has commenced a Phase 3 clinical trial of Epidiolex® (cannabidiol or CBD) as an adjunctive therapy for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic disorder, the most common symptom of which is epilepsy.
GW Pharma Reports Positive Results and Stock More than Doubles by Mid-Day
On March 14, 2016, GW Pharmaceuticals (NASDAQ: GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for the first pivotal Phase 3 study of Epidiolex, a CBD-based medicine, in treating Dravet syndrome, a severe form of pediatric epilepsy.
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex® (cannabidiol)
LONDON, March 14, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Dravet syndrome.
Merrill Lynch High on Marijuana
No one supposes that the core business of Bank of America, Merrill Lynch’s parent company, is social justice. But social investing is not a new idea.
The Cannabis Go-Betweens in a Legalization Affair
There are many ways to continue the investment affair with cannabis. Many products beside the plant could be your go-betweens.
Could Epidiolex Launch in 2017?
GW Pharma is reportedly ramping up production of Epidiolex in anticipation of FDA approval and the significant commercial demand for the drug that would follow.
Epidiolex Shows Promise in Latest Study
While the debate over the efficacy of medical marijuana continues, there is a growing body of evidence that suggests it may be helpful in treating patients suffering from intractable seizures.
Don’t Fight the Tape: Cannabis Stocks Subject to Broad Market Swings
Investors may be lulled into thinking that stocks they own or study in the cannabis space are insulated from what’s happening in the broader market. But that’s simply not true, and violates one of the oldest maxims in investing: Don’t fight the tape.
Florida Department of Health Funds Big Pharma Study
Last week, the Florida Department of Health announced it plans to use its earmarked CBD research funds to test Epidiolex, a drug patented and produced by the publicly traded pharmaceutical company, GW Pharma (NASDAQ: GWPH).
GWPH Business Plan: Alan Brochstein’s Thoughts
Alan Brochstein has followed quite closely recent developments in the medical and financial world insofar as they have affected GW Pharmaceuticals (NASDAQ: GWPH), the developer of two promising cannabis-based medications.
Are Cannabis Stocks Riding a Market Wave?
In the past few weeks we have seen some massive volatility in the most active cannabis stocks. At the same time we have seen broad market indexes like the NASDAQ and the S&P 500 hit new record highs, begging the question of whether the cannabis stocks are just following general momentum.
Friday Mind Your Order Type!
Cannabis stocks struggled on this Friday trading session. Volumes were low, profit taking in recent high flyers, and poor trading behavior to cap out the week.
Epidiolex Shows Promise for Patients and Investors
The American Academy of Neurology has reported promising results in early trials of the drug, Epidiolex, which is 98 percent pure cannabidiol, in treating severe forms of pediatric epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome.
Monday Hemp Retail Market Growth
Cannabis stocks began the week with mixed action. Volumes continue to be lackluster and some of the recently pumped stocks have now been left to crater.
Friday the 13th: Don’t Hide in the Shadows
Cannabis stocks were mostly lower today, not too surprising given the day of the week. Unfortunately, the earlier enthusiasm around the potentially game changing CARERS Act has quickly waned.
Friday Long Weekend
Volumes in the cannabis space were nonexistent. Not surprising given the general trend of Fridays and the day before a long weekend.
Tuesday Travel Now With Your US Dollar
Cannabis stocks are not feeling quite the same positive risk sentiment as the broader markets. Investors, traders and speculators may be feeling a bit of fatigue with these seasoned tickers, many of which will amount to nothing.
What the 5 Largest Cannabis Stocks Can Tell Us
The early leaders in market cap (the total value of publicly-traded equity) in a expanding industry like cannabis can tell us a lot. These companies have a lot of advantages by being on this perch, but also some responsibilities.
Top 5 Pot Stock Moments of 2014
For better or worse, here were five big moments for pot stocks in 2014: the good, the bad, the precedent-setting and the cringe-worthy.
Thursday Spread
Equities continued to surge higher and recoup the recent weakness. Keep in mind that just a few days ago, the market was off to its worst start to a calendar year ever.
Tuesday Biotech Versus Cannabis
U.S. Q3 GDP revisions came out today and the news was quite positive. The good old U.S. economy posted a 5% annualized growth rate.
Monday Issuing Stock: Shareholder Impact
One of the benefits of being a public company is the access to low cost capital. Public companies have the ability to issue stock versus other methods such as borrowing money.
Tuesday Tail Licking
Stocks take a tail licking globally, as many indices posted declines of more than 1%. Energy weakness has been a key reason for several weeks now.
Wednesday’s Key Questions to Consider
This morning’s November ADP jobs report came in with more than 200,000 jobs added. The U.S. economy continues to chug along, but this report was a bit softer than expected.